DUS4L (dihydrouridine synthase 4 like) primarily catalyzes synthesis of dihydrouridine, a modified base in the D-loop of most tRNAs, representing its canonical housekeeping function. However, emerging evidence reveals broader oncogenic roles beyond tRNA modification. DUS4L is significantly upregulated in lung adenocarcinoma (LUAD) tissues and promotes tumor progression through interaction with the signaling molecule GRB2, activating PI3K/AKT and ERK/MAPK pathways to induce epithelial-mesenchymal transition and enhance cell migration and invasion 1. DUS4L knockdown suppresses LUAD cell proliferation and promotes apoptosis, with affected genes enriched in spliceosome, ribosome, and p53 signaling pathways 2. Beyond cancer, DUS4L participates in the DUS4L-BCAP29 fusion transcript, which exists in normal tissues and promotes cell growth and neural differentiation 34. Additionally, DUS4L variants show potential clinical utility as biomarkers for early prediction of knee osteoarthritis progression using machine learning models 5. The gene's disruption has been documented in complex chr7 rearrangements associated with neurodevelopmental disorders 6. These findings establish DUS4L as a multifunctional protein with roles in tRNA modification, cancer progression, and potentially musculoskeletal disease, making it a candidate therapeutic target for LUAD.